Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3705 in Methylmalonic Acidemia
NCT04899310Phase 2Terminated
- Sponsor
- Moderna Inc
- Start
- Aug 2021
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
A Phase 2 trial of mRNA-3705 in methylmalonic acidemia (MMA), sponsored by Moderna Inc. Started Aug 2021; status: terminated.
02
Drugs
mRNA-3705
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on NCT04899310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899310.